The Filing Desk

Spyre Therapeutics

SYRE · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

SYRE · Last close · November 13, 2026
$104.00
Value Spyre Therapeutics yourself

Spyre Therapeutics reported revenue of $0 million in fiscal 2025.

SPYRE THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001636282-26-000020 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$155M
 
Free cash flow
—
 
Return on equity
−25.2%
34.1 pts
Market cap
$5.3B
Nov 13 close
P/E
—
 

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-25), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Spyre Therapeutics does

Spyre Therapeutics is a drug developer. It does not sell any medicine yet. It is working on antibody drugs for inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, and for rheumatic diseases such as rheumatoid arthritis.

Its pipeline has three antibody candidates, each aimed at a different target in the immune system: one called alpha-4 beta-7, one called TL1A and one called IL-23. The company changed each antibody so that it stays in the body longer, which could allow dosing by injection only every few months. It plans to test them alone and in pairs, because it believes a combined treatment could work better than one drug.

It also plans to test its TL1A antibody in other diseases, starting with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Spyre has never earned revenue from selling a product. It pays for its work with money raised from investors, and says it will need to raise more.

Its biggest risks, as it describes them

  • Needing to raise more money, which could dilute shareholders, and having no revenue from product sales.
  • Depending heavily on the success of a few antibody programs and their clinical trials.
  • Competition from other companies working on the same diseases and drug targets.
  • Early or interim trial results that may change as more patient data comes in.
  • Difficulty enrolling patients in trials, which could delay its development work.
From Spyre Therapeutics's annual report on Form 10-K, filed February 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Spyre Therapeutics lost money in fiscal 2025: a net loss of $155 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments9356339603756
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio4.9x4.2x10.7x11.3x13.2x
Quick ratio4.9x4.2x10.7x11.3x13.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Spyre Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Spyre Therapeutics shares on the open market, and 7 insiders sold $435.7 million, $34.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Scott L BurrowsChief Financial OfficerSold plan18,232$89.35$1.6 millionForm 4
Sep 2, 2026Heidy King-JonesSee RemarksSold plan400$90.00$36,000Form 4
Sep 1, 2026Heidy King-JonesSee RemarksSold plan27,999$87.31$2.4 millionForm 4
Sep 1, 2026Cameron TurtleChief Executive Officer, DirectorSold plan15,000$87.29$1.3 millionForm 4
Sep 1, 2026Scott L BurrowsChief Financial OfficerSold plan7,500$87.31$654,792Form 4
Aug 7, 2026Jeffrey W. AlbersDirectorSold plan23,000$104.53$2.4 millionForm 4
Aug 3, 2026Cameron TurtleChief Executive Officer, DirectorSold plan15,000$95.51$1.4 millionForm 4
Aug 3, 2026Scott L BurrowsChief Financial OfficerSold plan7,500$95.57$716,771Form 4
Jul 1, 2026Cameron TurtleChief Executive Officer, DirectorSold plan15,000$87.69$1.3 millionForm 4
Jul 1, 2026Sheldon SloanChief Medical OfficerSold plan8,334$87.70$730,896Form 4
Jul 1, 2026Scott L BurrowsChief Financial OfficerSold plan7,500$87.74$658,040Form 4
Jun 25, 2026Scott L BurrowsChief Financial OfficerSold15,000$87.13$1.3 millionForm 4
The latest 12 of 29 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−11,338.5%——
Altman Z''−3.484.4611.54
Accruals ratio−115.7%−10.7%2.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets———
Current ratio rosePassPassPass
Share count didn't riseFail——
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Spyre Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Spyre TherapeuticsFY25——————
Acadia PharmaceuticalsFY2511.9%9.8%9.8%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
Agios PharmaceuticalsFY2548.0%−873.9%−698.3%———Compare
AlkermesFY25−5.2%17.2%32.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue55400192100
Revenue growth—12.5%−25.3%−100.0%——−87.6%−62.0%−100.0%—
Gross profit——————————
Research and development1823376560575990163172
Operating income−22−28−46−80−82−66−85−242−209−210
Net income−22−27−44−78−81−66−84−339−208−155
Diluted EPS (US$)−55.50−45.00−53.25−61.25−38.00−25.02−24.8613.76——
Diluted shares (millions)01112337——
Cash flow
Cash from operations−19−25−32−66−76−54−80−100−157−169
Capital expenditure010241000—
Free cash flow−19−25−33−67−80−54−80−100−157—
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1245687264538
Balance sheet at fiscal year end
Cash and short-term investments645074721469356339603756
Debt incl. finance leases——————————
Total assets6756788316211071342608778
Total liabilities461023222621739162
Shareholders' equity635067601408450184518715
Margins and ratios
Gross margin——————————
Operating margin−473.3%−531.7%−1,169.3%——−350.3%−3,640.2%−27,348.0%——
Net margin−468.8%−523.3%−1,140.6%——−351.1%−3,598.8%−38,238.2%——
Free cash flow margin−411.7%−484.8%−838.9%——−289.7%−3,442.8%−11,276.5%——
Rule of 40 (growth + FCF margin)—−472.3%−864.2%———−3,530.3%−11,338.5%——
Return on capital——————————
Return on equity−106.5%−48.1%−75.3%−122.7%−80.9%−58.8%−124.9%−289.2%−59.3%−25.2%
Return on assets−41.0%−44.2%−66.3%−97.3%−66.1%−48.5%−92.6%−164.1%−43.8%−22.4%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Spyre Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Spyre Therapeutics.